1	VEGF-targeted	VEGF-targeted	B-NP	JJ	O	2	NMOD	-1
2	therapy	therapy	I-NP	NN	O	8	NMOD	0
3	:	:	O	:	O	2	P	-1
4	therapeutic	therapeutic	B-NP	JJ	O	5	AMOD	-1
5	potential	potential	I-NP	JJ	O	2	NMOD	0
6	and	and	I-NP	CC	O	8	NMOD	-1
7	recent	recent	I-NP	JJ	O	8	NMOD	-1
8	advances	advance	I-NP	NNS	O	0	ROOT	-1
9	.	.	O	.	O	8	P	-1

1	After	After	B-PP	IN	O	0	ROOT	-1
2	over	over	B-NP	IN	O	4	NMOD	-1
3	30	30	I-NP	CD	O	2	AMOD	-1
4	years	year	I-NP	NNS	O	1	PMOD	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	theorizing	theorize	B-NP	VBG	O	16	VMOD	-1
7	,	,	O	,	O	16	P	-1
8	the	the	B-NP	DT	O	9	NMOD	-1
9	use	use	I-NP	NN	O	16	SUB	0
10	of	of	B-PP	IN	O	9	NMOD	-1
11	angiogenesis	angiogenesis	B-NP	NN	O	12	NMOD	3	angiogenesis
12	inhibitors	inhibitor	I-NP	NNS	O	10	PMOD	-1
13	as	as	B-PP	IN	O	9	NMOD	-1
14	anticancer	anticancer	B-NP	JJ	O	15	NMOD	-1
15	therapy	therapy	I-NP	NN	O	13	PMOD	0
16	has	have	B-VP	VBZ	O	5	SBAR	-1
17	finally	finally	I-VP	RB	O	16	VMOD	-1
18	moved	move	I-VP	VBN	O	16	VC	-1
19	from	from	B-PP	IN	O	18	VMOD	-1
20	the	the	B-NP	DT	O	21	NMOD	-1
21	realm	realm	I-NP	NN	O	19	PMOD	-1
22	of	of	B-PP	IN	O	21	NMOD	-1
23	research	research	B-NP	NN	O	22	PMOD	-1
24	to	to	B-PP	TO	O	23	NMOD	-1
25	reality	reality	B-NP	NN	O	24	PMOD	-1
26	.	.	O	.	O	1	P	-1

1	Normal	Normal	B-NP	JJ	O	3	NMOD	-1
2	adult	adult	I-NP	JJ	O	3	NMOD	-1
3	vasculature	vasculature	I-NP	NN	O	4	SUB	-1
4	is	be	B-VP	VBZ	O	0	ROOT	-1
5	generally	generally	B-ADJP	RB	O	6	AMOD	-1
6	quiescent	quiescent	I-ADJP	JJ	O	4	PRD	-1
7	in	in	B-PP	IN	O	6	AMOD	-1
8	nature	nature	B-NP	NN	O	7	PMOD	-1
9	,	,	O	,	O	6	P	-1
10	with	with	B-PP	IN	O	6	AMOD	-1
11	endothelial	endothelial	B-NP	JJ	B-cell_type	12	NMOD	-1
12	cells	cell	I-NP	NNS	I-cell_type	10	PMOD	-1
13	dividing	divide	B-VP	VBG	O	12	NMOD	0
14	approximately	approximately	B-NP	RB	O	17	NMOD	-1
15	every	every	I-NP	DT	O	17	NMOD	-1
16	10	10	I-NP	CD	O	15	AMOD	-1
17	years	year	I-NP	NNS	O	13	OBJ	-1
18	.	.	O	.	O	4	P	-1

1	In	In	B-PP	IN	O	8	VMOD	-1
2	contrast	contrast	B-NP	NN	O	1	PMOD	-1
3	,	,	O	,	O	8	P	-1
4	the	the	B-NP	DT	O	5	NMOD	-1
5	growth	growth	I-NP	NN	O	8	SUB	4	growth
6	of	of	B-PP	IN	O	5	NMOD	-1
7	tumors	tumor	B-NP	NNS	O	6	PMOD	-1
8	requires	require	B-VP	VBZ	O	0	ROOT	17	requires
9	constant	constant	B-NP	JJ	O	11	NMOD	-1
10	vascular	vascular	I-NP	JJ	O	11	NMOD	-1
11	growth	growth	I-NP	NN	O	13	NMOD	4	growth
12	and	and	I-NP	CC	O	13	NMOD	-1
13	remodeling	remodeling	I-NP	NN	O	8	OBJ	7	remodeling
14	in	in	B-PP	IN	O	8	VMOD	-1
15	order	order	B-NP	NN	O	14	PMOD	-1
16	for	for	B-PP	IN	O	15	NMOD	-1
17	solid	solid	B-NP	JJ	O	18	NMOD	-1
18	tumors	tumor	I-NP	NNS	O	16	PMOD	-1
19	to	to	B-VP	TO	O	20	VMOD	-1
20	grow	grow	I-VP	VB	O	8	VMOD	4	grow
21	beyond	beyond	B-PP	IN	O	20	VMOD	-1
22	1-2	1-2	B-NP	CD	O	23	NMOD	-1
23	mm	mm	I-NP	NN	O	21	PMOD	-1
24	(	(	O	(	O	26	DEP	-1
25	3	3	B-NP	CD	O	26	DEP	-1
26	)	)	O	)	O	23	NMOD	-1
27	in	in	B-PP	IN	O	23	NMOD	-1
28	size	size	B-NP	NN	O	27	PMOD	-1
29	.	.	O	.	O	8	P	-1

1	Vascular	Vascular	B-NP	JJ	B-protein	4	NMOD	-1
2	endothelial	endothelial	I-NP	JJ	I-protein	4	NMOD	-1
3	growth	growth	I-NP	NN	I-protein	4	NMOD	0
4	factor	factor	I-NP	NN	I-protein	10	NMOD	-1
5	(	(	O	(	O	7	DEP	-1
6	VEGF	VEGF	B-NP	NN	B-protein	7	DEP	-1
7	)	)	O	)	O	4	NMOD	-1
8	and	and	O	CC	O	10	NMOD	-1
9	its	its	B-NP	PRP$	O	10	NMOD	-1
10	receptors	receptor	I-NP	NNS	O	11	SUB	-1
11	are	be	B-VP	VBP	O	0	ROOT	-1
12	key	key	B-NP	JJ	O	13	NMOD	-1
13	regulators	regulator	I-NP	NNS	O	11	PRD	-1
14	of	of	B-PP	IN	O	13	NMOD	-1
15	the	the	B-NP	DT	O	16	NMOD	-1
16	process	process	I-NP	NN	O	14	PMOD	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	angiogenesis	angiogenesis	B-NP	NN	O	17	PMOD	3	angiogenesis
19	,	,	O	,	O	18	P	-1
20	which	which	B-NP	WDT	O	18	NMOD	-1
21	makes	make	B-VP	VBZ	O	20	SBAR	-1
22	them	them	B-NP	PRP	O	25	NMOD	-1
23	attractive	attractive	B-NP	JJ	O	24	AMOD	-1
24	therapeutic	therapeutic	I-NP	JJ	O	25	NMOD	-1
25	targets	target	I-NP	NNS	O	21	OBJ	0
26	.	.	O	.	O	11	P	-1

1	A	A	B-NP	DT	O	2	NMOD	-1
2	multitude	multitude	I-NP	NN	O	7	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	VEGF-targeted	VEGF-targeted	B-NP	JJ	O	6	NMOD	-1
5	inhibitory	inhibitory	I-NP	JJ	O	6	NMOD	0
6	agents	agent	I-NP	NNS	O	3	PMOD	-1
7	are	be	B-VP	VBP	O	0	ROOT	-1
8	currently	currently	I-VP	RB	O	7	VMOD	-1
9	being	be	I-VP	VBG	O	7	VC	-1
10	investigated	investigate	I-VP	VBN	O	9	VC	-1
11	for	for	B-PP	IN	O	10	VMOD	-1
12	the	the	B-NP	DT	O	13	NMOD	-1
13	treatment	treatment	I-NP	NN	O	11	PMOD	0
14	of	of	B-PP	IN	O	13	NMOD	-1
15	cancer	cancer	B-NP	NN	O	14	PMOD	-1
16	.	.	O	.	O	7	P	-1

1	This	This	B-NP	DT	O	3	NMOD	-1
2	review	review	I-NP	NN	O	3	NMOD	-1
3	article	article	I-NP	NN	O	4	SUB	-1
4	focuses	focus	B-VP	VBZ	O	0	ROOT	-1
5	on	on	B-PP	IN	O	4	VMOD	-1
6	recent	recent	B-NP	JJ	O	7	NMOD	-1
7	developments	development	I-NP	NNS	O	5	PMOD	-1
8	in	in	B-PP	IN	O	7	NMOD	-1
9	the	the	B-NP	DT	O	10	NMOD	-1
10	use	use	I-NP	NN	O	8	PMOD	0
11	of	of	B-PP	IN	O	10	NMOD	-1
12	angiogenesis	angiogenesis	B-NP	NN	O	13	NMOD	3	angiogenesis
13	inhibitors	inhibitor	I-NP	NNS	O	11	PMOD	-1
14	for	for	B-PP	IN	O	10	NMOD	-1
15	the	the	B-NP	DT	O	16	NMOD	-1
16	treatment	treatment	I-NP	NN	O	14	PMOD	19	treatment
17	of	of	B-PP	IN	O	16	NMOD	-1
18	breast	breast	B-NP	NN	O	24	NMOD	-1
19	,	,	O	,	O	24	P	-1
20	lung	lung	B-NP	NN	O	24	NMOD	-1
21	,	,	O	,	O	24	P	-1
22	and	and	O	CC	O	24	NMOD	-1
23	colorectal	colorectal	B-NP	JJ	O	24	NMOD	-1
24	cancers	cancer	I-NP	NNS	O	17	PMOD	-1
25	.	.	O	.	O	4	P	-1

